Can autologous ovarian grafting protect function in patients with Premature Ovarian Insufficiency?

Autologous ovarian grafting involves taking a patient's own ovarian tissue and transplanting it into another site, such as subcutaneous tissue. This procedure is currently used to protect ovarian function in patients whose ovaries are at risk of damage from medical treatments like pelvic radiotherapy ⁵.

While the primary goal of this technique is to prevent hormone loss due to external factors (like radiation), researchers are also investigating various other methods to address the underlying causes of Premature Ovarian Insufficiency (POI).

What the research says

A phase II trial showed that autologous ovarian tissue grafting into subcutaneous tissue was effective at maintaining hormonal profiles in young women undergoing pelvic radiotherapy ⁵. In this study, 85% of patients who received the graft maintained hormone levels consistent with preserved ovarian function and did not experience symptoms of menopause (climacteric symptoms) at the six-month mark ⁵.

For patients specifically dealing with POI or other forms of ovarian failure, research is exploring several different biological approaches. These include using platelet-rich plasma (PRP) to improve the ovarian environment ¹, and using mesenchymal stem cells (MSCs) or their derivatives (extracellular vesicles) to repair tissue and restore hormone levels ⁴. Other research focuses on the role of the immune system and the gut-mitochondria axis in managing conditions like POI [2, 3].

What to ask your doctor

• Is autologous ovarian grafting an option for my specific type of ovarian insufficiency?
• What are the differences between surgical grafting and other treatments like platelet-rich plasma (PRP) or stem cell therapies?
• How would a graft compare to hormone replacement therapy in managing my symptoms?
• Are there any risks or limitations to using autologous tissue for my specific medical history?